Initial depression and response to imipramine in agoraphobia

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Agoraphobia is a debilitating anxiety disorder.
• Imipramine is a tricyclic antidepressant often used to treat agoraphobia.
• The precise mechanism of imipramine's efficacy in agoraphobia remains under investigation.

Purpose of the Study:

• To investigate the relationship between depression levels, imipramine dosage, and treatment response in agoraphobia patients.
• To determine if imipramine's effects in agoraphobia are primarily antidepressant.

Main Methods:

• Thirty-seven agoraphobia patients were enrolled in a controlled treatment study.
• Patients were classified as high or low depressed based on two depression measures.
• A 2x2 analysis of variance examined the effects of depression level and imipramine dosage.

Main Results:

• A significant main effect of imipramine dosage was observed.
• No significant main effect of depression level was found.
• A greater dose effect was noted in the low depressed group.
• High-dose imipramine yielded better response rates in patients with low initial depression.

Conclusions:

• Imipramine's beneficial effects in agoraphobia may not be solely due to its antidepressant properties.
• Treatment response appears modulated by the interplay between imipramine dosage and baseline depression levels.
• Further research is needed to elucidate the non-antidepressant mechanisms of imipramine in agoraphobia treatment.